New approaches in education and health sciences management

New approaches in education and health sciences management

Evaluation of the Therapeutic Effects of Saffrotin Tablets on ESR Levels in Patients with Fibromyalgia

Document Type : Original Article

Authors
Mehri Behzad Khameslo 1
Mohsen Ebrahimi 1
Mostafa Behzad khamesloo 2
1 Department of Sport Sciences, Faculty of Humanities, Semnan University, Semnan, Iran
2 Health Technology and Growth Center, Mazandaran University of Medical Sciences, Sari, Iran
10.22034/edus.2025.558946.1068
Abstract
Introduction: Fibromyalgia is a chronic musculoskeletal pain disorder characterized by widespread pain, fatigue, sleep disturbances, and mood problems, with a higher prevalence among women. Emerging evidence suggests that low-grade systemic inflammation may contribute to the persistence of symptoms in these patients. On the other hand, natural compounds such as saffron and its derivatives, including Saffrotin tablets, possess anti-inflammatory, antioxidant, and neuroregulatory properties that may help improve the condition of patients with fibromyalgia by reducing inflammatory markers. Therefore, the present study aimed to evaluate the therapeutic effects of Saffrotin tablets on serum ESR levels in patients with fibromyalgia.
Methods: This quasi-experimental study with a pretest–posttest design was conducted in 2019 on 16 female patients with fibromyalgia at Imam Khomeini Hospital in Sari, Iran. Participants were purposefully selected and randomly assigned to two groups: Saffrotin and placebo. The intervention group received Saffrotin tablets (30 mg, twice daily) for a specified duration. Blood samples were collected from all participants before and after the intervention, and serum ESR levels were measured using the standard Westergren method. Data were analyzed using paired and independent t-tests in SPSS software.
Results: The findings showed that Saffrotin supplementation significantly reduced serum ESR levels compared to the control group, whereas no significant changes were observed in the placebo group. This reduction indicated a notable anti-inflammatory effect of Saffrotin and a potential improvement in the inflammatory status of patients.
Conclusion: In conclusion, Saffrotin, as a natural and safe herbal supplement, has the potential to serve as an adjunctive therapy in patients with fibromyalgia. By modulating inflammatory and oxidative stress pathways, it may help reduce symptoms and improve patients’ quality of life. However, studies with larger sample sizes, longer treatment durations, and evaluation of additional inflammatory markers are recommended to confirm the stability and underlying mechanisms of these effects
Keywords
Saffrotin
ESR
Fibromyalgia

Ethics Approval ID: IR.MAZUMS.REC.1398.1166

IRCT Registration Number: IRCT20191125045496N2

1.         Shao X, Fu X, Yang J, Sui W, Li S, Yang W, et al. The asymmetrical ESR signaling in muscle progenitor cells determines the progression of adolescent idiopathic scoliosis. Cell Discov. 2023 ;9(1):44. doi: 10.1038/s41421-023-00531-5
2.         Herzog SK, Fuqua SAW. ESR mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022;126(2):174-186. doi: 10.1038/s41416-021-01564-x
3.         Sarzi-Puttini P, Giorgi V, Atzeni F, Gorla R, Kosek E, Choy EH, et al. Fibromyalgia position paper. Clin Exp Rheumatol. 2021;39 Suppl 130(3):186-193. doi: 10.55563/clinexprheumatol/i19pig
4.         Boulis M, Boulis M, Clauw D. Magnesium and Fibromyalgia: A Literature Review. J Prim Care Community Health. 2021;12:21501327211038433. doi: 10.1177/21501327211038433
5.         Bair MJ, Krebs EE. Fibromyalgia. Ann Intern Med. 2020;172(5):ITC33-ITC48. doi: 10.7326/AITC202003030
6.         Giorgi V, Sirotti S, Romano ME, Marotto D, Ablin JN, Salaffi F, Sarzi-Puttini P. Fibromyalgia: one year in review 2022. Clin Exp Rheumatol. 2022;40(6):1065-1072. doi: 10.55563/clinexprheumatol/if9gk2
7.         Maffei ME. Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies. Int J Mol Sci. 2020;21(21):7877. doi: 10.3390/ijms21217877
8. Brett JO, Spring LM, Bardia A, Wander SA. ESR mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23(1):85. 10.1186/s13058-021-01462-3
9. Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16(11):645-660. 10.1038/s41584-020-00506-w
10. Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125(21):3714-3728. 10.1002/cncr.32345
11. Siracusa R, Paola RD, Cuzzocrea S, Impellizzeri D. Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update. Int J Mol Sci. 2021;22(8):3891. 10.3390/ijms22083891
12. Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, et al. ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. Clin Cancer Res. 2020;26(19):5172-5177. doi: 10.1158/1078-0432.CCR-20-0224  
New approaches in education and health sciences management
Volume 2, Issue 4
January 2026
Winter 2026
Pages 1-10

  • Receive Date 26 June 2025
  • Revise Date 21 August 2025
  • Accept Date 05 November 2025
  • First Publish Date 11 November 2025
  • Publish Date 22 December 2025